(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 30.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.71%.
Tg Therapeutics's revenue in 2025 is $454,068,000.On average, 3 Wall Street analysts forecast TGTX's revenue for 2025 to be $92,275,160,552, with the lowest TGTX revenue forecast at $91,155,139,990, and the highest TGTX revenue forecast at $92,993,915,779. On average, 3 Wall Street analysts forecast TGTX's revenue for 2026 to be $129,545,237,049, with the lowest TGTX revenue forecast at $109,891,962,229, and the highest TGTX revenue forecast at $145,099,703,089.
In 2027, TGTX is forecast to generate $157,577,166,895 in revenue, with the lowest revenue forecast at $140,374,799,799 and the highest revenue forecast at $181,481,728,149.